Printer Friendly

ANGEION RELEASES FIFTH PRODUCT FAMILY

 ANGEION RELEASES FIFTH PRODUCT FAMILY
 MINNEAPOLIS, May 22 /PRNewswire/ -- Angeion Corporation


(NASDAQ: ANGN) has released its fifth family of proprietary products, the TYSHAK(TM) Pediatric Balloon Dilatation Catheter.
 The device is used in pediatric interventional cardiology, a specialized market currently under served by the medical device industry. The micro-thin balloon material enables the physician to insert the catheter through a very small puncture, which is important for pediatric procedures.
 "The TYSHAK balloon catheter has two important advantages: The product has the lowest profile balloons available in the market for pediatric use. This allows large balloons to be inserted through a very small sheath. Secondly, the device provides maximum trackability over a guidewire," said nationally recognized pediatric interventional cardiologist Ziyad Hijazi, M.D., from the New England Medical Center, Tufts University School of Medicine.
 The TYSHAK was released to the market April 1 and is available in 42 sizes. Initial sales and customer response has exceeded expectations. Angeion will seek to expand its distribution of the product to the international marketplace.
 The addition of the TYSHAK family to Angeion's proprietary product line creates an ideal opportunity to access a specialized market which is synergistic with other Angeion product lines. Through its five product families, Angeion manufactures and sells a total of 100 individual products.
 Angeion continues to proceed with its investment banker Piper Jaffray on two separate financing efforts underway to fund its research and development projects.
 Minneapolis-based Angeion Corporation, through its Angeion Medical Products Division, manufactures interventional accessory devices primarily for the cardiovascular markets. Angeion's subsidiaries, AngeLase, Inc. and AngeMed, Inc., are developing products for treating various types of arrhythmias.
 -0- 5/22/92
 /CONTACT: Brenda Roth of Angeion, 612-550-9388/
 (ANGN) CO: Angeion Corporation ST: Minnesota IN: MTC SU: PDT


KH -- MN006 -- 3262 05/22/92 11:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 22, 1992
Words:299
Previous Article:FIAT FINANCE USA $1 BILLION COMMERCIAL PAPER PROGRAM RATED 'F-1' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:SETTLEMENT ANNOUNCED IN LONG-STANDING DISPUTE AMONG TITLE INSURANCE COMPANIES IN NORTH CAROLINA
Topics:


Related Articles
ANGEION RECEIVES ADDITIONAL MARKET APPROVAL FROM JAPANESE GOVERNMENT
ANGEION TO EXPLORE SALE OF MEDICAL PRODUCTS DIVISION
ANGEION SIGNS AGREEMENT WITH GERMAN DISTRIBUTOR
ANGEION REPORTS THIRD QUARTER FIGURES
ANGEION SELLS ACCESSORY DIVISION; FOCUSES EXCLUSIVELY ON TREATING ARRHYTHMIAS
ANGEION RELEASES SECOND QUARTER FIGURES
ANGEION REPORTS THIRD QUARTER FIGURES
Angeion Corporation Receives Permission to Begin U.S. Clinicals on its 2020 Family of ICDs
Angeion Corporation Receives CE Approval for Model 2020 Series of ICDs
Angeion Receives Pre-Market Approval from FDA for Sentinel ICDs; Compact, Feature Intensive ICDs to be Marketed to $960 Million U.S. Industry

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters